These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 21973023)

  • 21. Resveratrol sensitized leukemia stem cell-like KG-1a cells to cytokine-induced killer cells-mediated cytolysis through NKG2D ligands and TRAIL receptors.
    Hu L; Cao D; Li Y; He Y; Guo K
    Cancer Biol Ther; 2012 May; 13(7):516-26. PubMed ID: 22406996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression.
    Decot V; Voillard L; Latger-Cannard V; Aissi-Rothé L; Perrier P; Stoltz JF; Bensoussan D
    Exp Hematol; 2010 May; 38(5):351-62. PubMed ID: 20172016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.
    Wang Y; Bo J; Dai HR; Lu XC; Lv HY; Yang B; Wang T; Han WD
    Exp Hematol; 2013 Mar; 41(3):241-52.e3. PubMed ID: 23123634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3+CD56+ cells and downregulating regulatory T cells as well as IL-35.
    Tao Q; Chen T; Tao L; Wang H; Pan Y; Xiong S; Zhai Z
    J Immunother; 2013; 36(9):462-7. PubMed ID: 24145357
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunomagnetic selection or irradiation eliminates alloreactive cells but also reduces anti-tumor potential of cytokine-induced killer cells: implications for unmanipulated cytokine-induced killer cell infusion.
    Rettinger E; Kreyenberg H; Merker M; Kuçi S; Willasch A; Bug G; Ullrich E; Wels WS; Bonig H; Klingebiel T; Bader P
    Cytotherapy; 2014 Jun; 16(6):835-44. PubMed ID: 24582456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Autologous CIK cell infusion promotes amplification ability of CD3⁺ CD56⁺ cells when re-preparation from patients with malignant tumors].
    Yu H; Sun Y; Lin D; Li C; Chen W; Ma D
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):748-53, 758. PubMed ID: 25001943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts.
    Poh SL; Linn YC
    Cancer Immunol Immunother; 2016 May; 65(5):525-36. PubMed ID: 26961084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma.
    Pfeffermann LM; Pfirrmann V; Huenecke S; Bremm M; Bonig H; Kvasnicka HM; Klingebiel T; Bader P; Rettinger E
    Cytotherapy; 2018 Jun; 20(6):839-850. PubMed ID: 29754771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal.
    Marin V; Kakuda H; Dander E; Imai C; Campana D; Biondi A; D'Amico G
    Exp Hematol; 2007 Sep; 35(9):1388-97. PubMed ID: 17656004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their
    Heinze A; Grebe B; Bremm M; Huenecke S; Munir TA; Graafen L; Frueh JT; Merker M; Rettinger E; Soerensen J; Klingebiel T; Bader P; Ullrich E; Cappel C
    Front Immunol; 2019; 10():2816. PubMed ID: 31849984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy.
    Helms MW; Prescher JA; Cao YA; Schaffert S; Contag CH
    Cancer Immunol Immunother; 2010 Sep; 59(9):1325-34. PubMed ID: 20532883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML.
    Schlegel P; Ditthard K; Lang P; Mezger M; Michaelis S; Handgretinger R; Pfeiffer M
    J Immunol Res; 2015; 2015():473175. PubMed ID: 26236752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells.
    Lu X; Zhu A; Cai X; Jia Z; Han W; Ma L; Zhou M; Qian K; Cen L; Chen B
    Cancer Biol Ther; 2012 Jun; 13(8):623-9. PubMed ID: 22555808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can the dual-functional capability of CIK cells be used to improve antitumor effects?
    Wang X; Yu W; Li H; Yu J; Zhang X; Ren X; Cao S
    Cell Immunol; 2014 Jan; 287(1):18-22. PubMed ID: 24355711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity.
    Lefterova P; Märten A; Buttgereit P; Weineck S; Scheffold C; Huhn D; Schmidt-Wolf IG
    J Immunother; 2000; 23(3):304-10. PubMed ID: 10838659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells.
    Boerman GH; van Ostaijen-ten Dam MM; Kraal KC; Santos SJ; Ball LM; Lankester AC; Schilham MW; Egeler RM; van Tol MJ
    Cancer Immunol Immunother; 2015 May; 64(5):573-83. PubMed ID: 25854581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
    Laport GG; Sheehan K; Baker J; Armstrong R; Wong RM; Lowsky R; Johnston LJ; Shizuru JA; Miklos D; Arai S; Benjamin JE; Weng WK; Negrin RS
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1679-87. PubMed ID: 21664472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Roles of NKG2D in cytokine-induced killer (CIK) against hematological malignant cells lines].
    He JY; Jia ZX; Cai XH; Han WM; Xiao R; Ma LD; Lu XZ; Zhou M; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1380-4. PubMed ID: 24370015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
    Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
    J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.